Description
What’s Driving Growth in the IVD Market in 2022?
What Major Trends are Affecting the Market in 2022?
How Has COVID-19 Impacted and Continued to Impact the Market in 2022?
What Product Trends and New Developments Will Shape the IVD Market in 2022?
Diagnostic test products have never been more important. This report is an update of the market for in vitro diagnostics products from Kalorama’s analysts to reflect the latest information as of Q1 2022.
The demand for testing and movement of current and new technologies has continued to demonstrate gains in most areas of the IVD market. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly evolving market picture. There are some growing segments in the market that have attracted industry attention. Among these are next-generation sequencing (NGS), personalized medicine and mass spectrometry. Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are also segments of great market interest, anticipated to be a core part of the future of IVD. The IVD market remains dynamic, demonstrating constant innovations.
Kalorama Information continues to be diligent in outlining the IVD market and its rapidly changing landscape. Kalorama Information has been and continues to be superior in accessing the market due to the extensive experience of its authors and commitment by the company to present the most accurate data available.
Table of Contents
Chapter One: Worldwide IVD Market – March 2022 Update
IVD Market Demand and Growth
- Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2021
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2021 ($ million) (Clinical Chemistry; Immunoassays – non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology – Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
- Figure 1-2: IVD Segment Performance, Q1 2021 – Q4 2021 ($MN)
- Figure 1-3: IVD Segment Performance, Total Market Value, 2021 ($MN)
COVID-19 Diagnostic Markets
Effect of COVID-19 on Market Segments
- Table 1-2: IVD Market excluding and with COVID-19, 2021
- Figure 1-4: IVD Market Distribution by Segment
- Table 1-3: Global In Vitro Diagnostic Market – YoY Growth 2020-2021
- Figure 1-5: Global In Vitro Diagnostic Market – YoY Growth 2020-2021
Chapter Two: Product Trends and New Developments
Selected New – Q4 2021 and Q1 2022 – Core IVD Product Launches, Developments and Trends
Clinical Chemistry
Flow Cytometry
Immunoassay
Mass Spectrometry
Molecular
Personalized Medicine
POC
Sequencing
COVID-19 Developments – Q1 2021 Through Q4 2021
- Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2021 Estimates – Rapid Testing Markets Remain Strong
Antigen
Molecular
Chapter Three: Top IVD Market Participant Results
Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2020-2021
- Figure 3-2: Changes in Market Distribution for IVD Sales, 2019 & 2021 – Roche and Abbott Tie for #1 Spot
2021 M&A Activity
- Table 3-1: IVD-Relevant M&A Activity, 2021
- Figure 3-3: Count of IVD Industry M&A Deals by Month, 2021
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
- Figure 3-4: Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19, BinaxNOW/ID NOW) Full Year 2020 and 2021
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
- Figure 3-5: BD Life Sciences, Revenues by Business FY End September 30, 2020, and 2021
bioMérieux SA
- Table 3-4: bioMérieux Corporate Summary
- Figure 3-6: bioMérieux Clinical Applications Segment, Full Year Results, 2020,2021
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
- Figure 3-7: Danaher Diagnostic Segment Performance, Full Year Results, 2020,2021
Hologic, Inc.
- Table 3-6: Hologic Corporate Summary
- Figure 3-8: Hologic Diagnostic Segment Performance, Full Year Results, FY 2020, FY 2021, $M
Ortho Clinical Diagnostics
- Table 3-7: Ortho Clinical Corporate Summary
- Figure 3-9: Ortho Clinical Diagnostics, Full Year Results, $M (2020, 2021)
PerkinElmer, Inc.
- Table 3-8: Perkin Elmer Corporate Summary
- Figure 3-10: PerkinElmer Diagnostics (Product, Service Revenue), Full Year Results, $M (2020, 2021)
Quidel Corporation
- Table 3-9: Quidel Corporate Summary
- Figure 3-11: Quidel Corporation Revenue by Product Group, Full Year Results 2020, 2021, $M
Roche Diagnostic
- Table 3-10: Roche Diagnostic Corporate Summary
- Figure 3-12: Roche Diagnostics Revenue by Product Group, Full Year Results 2020, 2021, CHF MN
Siemens Healthineers
- Table 3-11: Siemens Healthineers Corporate Summary
- Figure 3-13: Siemens Diagnostics Revenue, FY 2020 and FY 2021, € MN
Sysmex Corporation
- Table 3-12: Sysmex Corporate Summary
- Figure 3-14: Sysmex Revenue by Product Segment, FY 2020, 2021 and 2022, JPY MN
Thermo Fisher Scientific
- Table 3-13: Thermo Fisher Scientific Corporate Summary
- Figure 3-15: Thermo Fisher Scientific COVID-19 Response Revenue, 2020 and 2021 by Quarter
Chapter Four: New Opportunities
Artificial Intelligence in the Lab
Multiplex and Syndromic Testing
Advancing Lateral Flow Technologies
Personalized Medicine
Point-of-Care
Mass Spectrometry-based COVID-19 Testing
